HUTCHMED

Update in progress

HCM (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

HUTCHMED (China) Limited discovers, develops, and commercializes targeted cancer therapies and immunotherapies for cancer and immune diseases. Headquartered in Hong Kong, it operates in Hong Kong, the U.S., and globally. Core drugs include Fruquintinib (VEGFR inhibitor) for CRC and other cancers; Savolitinib (MET inhibitor) for NSCLC and RCC; Surufatinib; Sovleplenib; Tazemetostat; Fanregratinib; Ranosidenib. It also develops HMPL-760 and HMPL-506 and collaborates with major partners.

Company score

Sentiment: 0.12; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.07; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive